Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer

Last updated: March 3, 2026
Sponsor: M.D. Anderson Cancer Center
Overall Status: Active - Not Recruiting

Phase

2

Condition

Breast Cancer

Treatment

Therapeutic Conventional Surgery

Radiation Therapy

Clinical Study ID

NCT03359954
2017-0362
2017-0362
NCI-2018-00993
  • Ages > 18
  • All Genders

Study Summary

This phase II trial studies how well radiation therapy before surgery works in treating patients with hormone receptor positive, HER2 negative breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Inclusion:

  • Age >/=18 years at time of study entry

  • Histologically confirmed HR+/HER2- (according to American Society of Clinical Oncology/College of American Pathologists guidelines) invasive carcinoma of the breast

  • Presence of a clip in the primary breast cancer

  • Biopsy-amenable residual disease in the breast measuring >/= 1cm in at least one dimension on ultrasound cm in at least one dimension on ultrasound

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

  • Signed written informed consent

  • Planned for multidisciplinary evaluation by a Breast Surgical Oncologist and Breast Radiation Oncologist. For patients undergoing mastectomy and desirous of reconstruction or those undergoing breast conservation in whom oncoplastic local tissue rearrangement or reduction mammoplasty is being considered, this multidisciplinary evaluation will also include a plastic surgeon.

Exclusion:

  • Women who are pregnant or breast-feeding

  • Contraindication to receive radiotherapy

Study Design

Total Participants: 25
Treatment Group(s): 2
Primary Treatment: Therapeutic Conventional Surgery
Phase: 2
Study Start date:
November 16, 2017
Estimated Completion Date:
October 31, 2027

Study Description

PRIMARY OBJECTIVES:

I. To evaluate the change in percent tumor-infiltrating lymphocytes (TIL) as a continuous variable before and after preoperative boost radiotherapy (RT) in hormone receptor (HR)+/human epidermal growth factor receptor2 (HER2)- breast cancers.

SECONDARY OBJECTIVES:

I. To evaluate the safety of preoperative boost RT administered to patients with HR+/HER2- breast cancer.

EXPLORATORY OBJECTIVES:

  • I. To assess the mechanisms of cell death induced by preoperative boost RT.

  • II. To assess immunologic and molecular responses to preoperative boost RT.

  • III. To assess the correlations between immune markers, cell death markers, and their changes during treatment.

  • IV. To determine if magnetic resonance imaging (MRI) can be used to predict breast tumor response to neoadjuvant radiation.

OUTLINE:

Patients undergo boost radiation therapy 6-8 days before breast surgery. After surgery, patients continue to receive standard of care radiation therapy.

After completion of study treatment, patients are followed up at 6 months.

Connect with a study center

  • M D Anderson Cancer Center

    Houston, Texas 77030
    United States

    Site Not Available

  • M D Anderson Cancer Center

    Houston 4699066, Texas 4736286 77030
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.